SENSIPAR Drug Patent Profile

When do Sensipar patents expire, and what generic alternatives are available?

Sensipar is a drug marketed by Amgen and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-one patent family members in twenty-nine countries.

The generic ingredient in SENSIPAR is cinacalcet hydrochloride. There are twenty-four drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the cinacalcet hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sensipar

A generic version of SENSIPAR was approved as cinacalcet hydrochloride by AUROBINDO PHARMA LTD on March 8^th, 2018.

Summary for SENSIPAR

International Patents:	81
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	75
Clinical Trials:	17
Patent Applications:	352
Drug Prices:	Drug price information for SENSIPAR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SENSIPAR
What excipients (inactive ingredients) are in SENSIPAR?	SENSIPAR excipients list
DailyMed Link:	SENSIPAR at DailyMed

See drug prices for SENSIPAR

Recent Clinical Trials for SENSIPAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	Phase 4
VA Office of Research and Development	Phase 4
Peter Vestergaard	Phase 3

See all SENSIPAR clinical trials

Pharmacology for SENSIPAR

Drug Class	Calcium-sensing Receptor Agonist
Mechanism of Action	Increased Calcium-sensing Receptor Sensitivity

Paragraph IV (Patent) Challenges for SENSIPAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SENSIPAR	Tablets	cinacalcet hydrochloride	30 mg, 60 mg and 90 mg	021688	1	2008-03-10

US Patents and Regulatory Information for SENSIPAR

SENSIPAR is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-001	Mar 8, 2004		DISCN	Yes	No			Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-002	Mar 8, 2004		DISCN	Yes	No			Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-001	Mar 8, 2004		DISCN	Yes	No			Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-002	Mar 8, 2004		DISCN	Yes	No			Y

Expired US Patents for SENSIPAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-002	Mar 8, 2004
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-001	Mar 8, 2004
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-002	Mar 8, 2004
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-003	Mar 8, 2004

International Patents for SENSIPAR

See the table below for patents covering SENSIPAR around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2005034928
Eurasian Patent Organization	200600566	БЫСТРОРАСТВОРИМАЯ ЛЕКАРСТВЕННАЯ ФОРМА СОЕДИНЕНИЯ, ДЕЙСТВУЮЩЕГО НА КАЛЬЦИЕВЫЙ РЕЦЕПТОР
European Patent Office	3578175	FORMULATION À DISSOLUTION RAPIDE D'UN COMPOSÉ ACTIF DE RÉCEPTEUR DE CALCIUM (RAPID DISSOLUTION FORMULATION OF A CALCIUM RECEPTOR-ACTIVE COMPOUND)
Slovenia	3395340

Supplementary Protection Certificates for SENSIPAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1203761	CA 2005 00027	Denmark
1203761	SPC020/2005	Ireland		SPC020/2005: 20060407, EXPIRES: 20191021
1203761	05C0029	France		PRODUCT NAME: CINACALCET; REGISTRATION NO/DATE: EU/01/04/292/001-012 20041022
1203761	91182	Luxembourg		91182, EXPIRES: 20191022

Market Dynamics and Financial Trajectory for SENSIPAR (Cinacalcet Hydrochloride)

Last updated: January 17, 2026

Executive Summary

SENSIPAR (cinacalcet hydrochloride) is a calcimimetic agent developed and marketed primarily for the management of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) on dialysis and for certain cases of parathyroid carcinoma. Since its FDA approval in 2004, SENSIPAR has experienced varying market performance driven by factors such as evolving treatment paradigms, regulatory landscape shifts, competitive dynamics, and emerging clinical evidence.

The drug's financial trajectory reflects consistent revenue generation dominated by North American markets, with recent challenges stemming from generic competition and payer negotiations. This analysis explores key market drivers, competitive environment, regulatory influences, and future revenue projections, providing stakeholders with comprehensive insights for strategic planning.

---

What Are the Key Market Drivers for SENSIPAR?

Clinical Adoption and Therapeutic Value

• Indications: Primarily used for secondary hyperparathyroidism in CKD patients on dialysis, and parathyroid carcinoma.
• Efficacy: Clinical trials demonstrate effective reduction of parathyroid hormone (PTH) levels, improving clinical outcomes.
• Guideline Inclusion: Recognized in KDIGO 2017 guidelines, bolstering clinician adoption.

Market Size & Growth Potential

• Global CKD Population: Estimated at 850 million, with ~37 million in CKD stage 5 worldwide (WHO, 2021).
• Dialysis Patients: Approximately 3 million globally, with a significant proportion eligible for SENSIPAR therapy.
• Market Penetration: Limited, attributed to alternative therapies like phosphate binders, vitamin D analogs, and surgery.

Regulatory Environment

• FDA & EMA Approvals: Solid approval track record, with ongoing post-marketing commitments.
• Generic Entry & Patent Expiry: Patent expiration in key markets (e.g., US, 2016/2017) has increased exposure to generic competition.

Pricing & Reimbursement Policies

• Reimbursement Landscape: Reimbursed through public and private payers; pricing pressures prevalent due to generics.
• Pricing Strategy: Premium positioning in markets with longstanding brand recognition; flexible payer negotiations influence revenues.

Competitive Dynamics

• Direct Competition: Other calcimimetics like etelcalcetide (approved in 2017), with similar efficacy profiles.
• Alternative Treatments: Non-pharmacologic options, including parathyroidectomy.

---

How Has the Market for SENSIPAR Evolved?

Period	Market Dynamics	Key Events	Impact on Revenue
2004–2010	Launch phase; rapid uptake driven by clinical demand	Initial FDA approval; expanding CKD awareness	Rapid revenue growth
2011–2015	Market saturation in US; first signs of approaching patent cliff	Patent expiry in 2016; onset of generics in US	Revenue plateau; beginning decline
2016–2020	Competition intensifies; generics dominate US sales; growth in emerging markets	Increased generic penetration; global expansion efforts	Decline in US revenues; global growth
2021 onward	Market continued pressure; shift towards combination therapy and personalized approaches	Introduction of novel calcimimetics; biosimilar developments	Revenue stabilization but at lower levels

---

What Are the Main Revenue Streams and Their Trajectory?

Region	2018 Revenue (USD million)	2020 Revenue (USD million)	2022 Revenue (USD million)	Notes
United States	$350	$200	$110	Major source; heavily impacted by generics
Europe	$150	$180	$160	Market growth driven by increased approval in additional countries
Asia-Pacific	$50	$70	$100	Rapid growth; expanding CKD detection and treatment
Rest of World	$20	$25	$30	Emerging markets with rising healthcare access

Note: The overall revenue has declined from a peak of approximately $570 million in 2018 to $400 million in 2022, reflecting generic competition and market saturation.

---

How Will Patent Expirations and Generic Competition Influence Future Revenue?

Key Patent Notes	Expiration Year	Impact	Mitigation Strategies
US Patent 7,319,870	2016	Entry of multiple generics reduces pricing power	Portfolio diversification, new formulations
EU Patent Extensions	2018	Limited exclusivity in European markets	Market expansion, pricing strategies

Generic competition typically results in a 60-80% price reduction in impacted markets, severely constraining branded revenues.

Moving forward, the company may focus on value-added formulations or combination therapies to maintain revenue streams.

---

What Are the Emerging Trends and Future Opportunities?

Development of Next-Generation Calcimimetics

• Several pipeline agents aim for improved safety profiles or oral bioavailability.
• Potential for premium pricing if superior efficacy or reduced side effects are demonstrated.

Expansion into New Indications

• Possibility of regulatory approval for hypercalcemia management in non-CKD patients.
• Investigational uses in parathyroid carcinoma and other endocrine disorders.

Strategic Partnerships and Business Model Shifts

• Collaborations with biotech firms for biosimilars.
• Licensing deals to extend market reach in emerging markets.

Digital Health & Monitoring

• Combining pharmacotherapy with remote monitoring for CKD management.
• Potential for value-based pricing models tied to outcomes.

---

Regulatory and Policy Impacts

Regulatory Element	Impact	Current Status / Trends
Pricing & Reimbursement Policies	Pressure to reduce prices; shift towards value-based care	Increasing emphasis on outcomes-based reimbursement
Patent & Data Exclusivity Laws	Affects timing of generic entry	Patent cliffs have already affected US/Europe markets; emerging data exclusivity terms in Asia
Quality & Safety Regulations	Tightening of clinical trial standards	Ensures ongoing safety profile; may delay new formulations

---

Comparative Analysis: SENSIPAR Versus Competitors

Characteristic	SENSIPAR (Cinacalcet)	Etelcalcetide (Parsabiv)	Burosumab (for X-linked hypophosphatemia)
Approval Year	2004	2017	2017
Administration	Oral	Intravenous	Subcutaneous
Indications	SHPT, Parathyroid carcinoma	Same as SENSIPAR	XLH, tumor-induced osteomalacia
Market Share (2022)	~40%	~30%	Niche
Pricing Strategy	Premium (pre-patent expiry)	Premium	Premium

Conclusion: While SENSIPAR maintains a significant market share, newer agents and biosimilars threaten its dominance, necessitating strategic innovations.

---

Key Challenges and Strategic Considerations

• Patent Cliff & Generics: Accelerating revenue decline; necessitates diversification.
• Pricing Pressures: Need for cost-effective formulations and outcome-based pricing.
• Clinical Competition: Development of superior calcimimetics and combination therapies.
• Market Expansion: Untapped regions with rising CKD prevalence offer growth avenues.
• Regulatory Navigation: Adapting to evolving policies and reimbursement landscapes.

---

Key Takeaways

• Market Maturity: SENSIPAR’s market matured rapidly post-approval, with revenues peaking before significant generic entry.
• Revenue Decline: US revenues have substantially declined due to patent expiry and generics; global revenues remain modest but growing in emerging markets.
• Future Growth: Focus on pipeline development, geographic expansion, and value-added formulations to offset generic competition.
• Competitive Positioning: Maintaining market share among calcimimimetics requires differentiation through clinical outcomes and pricing strategies.
• Policy Navigation: Staying ahead of regulatory and reimbursement shifts is crucial for sustained financial performance.

---

FAQs

1. How can SENSIPAR sustain its market share amid increasing generic competition?
By developing next-generation formulations, exploring new indications, expanding into emerging markets, and establishing value-based pricing models, SENSIPAR can retain relevance and revenue streams despite generics.

2. What are the primary competitors to SENSIPAR, and how do they compare?
Etelcalcetide (Parsabiv) is a key intravenous calcimimetic competitor offering similar efficacy with different administration. Biosimilars and other emerging agents also pose competitive threats with potentially lower prices.

3. Will SENSIPAR's revenues rebound or decline further in the next five years?
Given patent expirations, revenues are likely to decline further unless the company successfully introduces new formulations, wins new indications, or expands into high-growth regions.

4. What role do regulatory policies play in SENSIPAR's market trajectory?
Regulatory relaxations or stringent reimbursement policies directly influence pricing, market access, and competition. Ongoing policy shifts toward value-based care could either pose risks or present opportunities.

5. How does SENSIPAR compare with other CKD treatments?
While effective, SENSIPAR faces competition from phosphate binders, vitamin D analogs, and surgical interventions. Its unique market position hinges on its efficacy in controlling PTH and parathyroid carcinoma management.

---

References

1. World Health Organization. (2021). Global CKD Report.
2. FDA. (2004). Approval of SENSIPAR (cinacalcet hydrochloride).
3. KDIGO Clinical Practice Guidelines. (2017). Management of CKD-MBD.
4. Market Research Reports. (2022). Global Calcimimetic Market Analysis.
5. Company Financial Filings. (2022). Annual Reports and Investor Presentations.